Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Diamondback Energy IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs Neurocrine Biosciences Inc — how do they compare? Diamondback Energy Inc trades at $200.71 (market cap $56.48B), while Neurocrine Biosciences Inc trades at $156.4 (market cap $16.46B). The key difference: Diamondback Energy Inc is far larger — about 3.4× Neurocrine Biosciences Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

FANGNBIX
Market Cap
$56.48B$16.46B
Sector
EnergyHealth
52-Week High
$213.69$185.50
52-Week Low
$134.53$123.10
Enterprise Value
$68.63B$16.48B
Dividend Yield
2.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $200.97, up 1.01% with strong bullish technical signals and positive earnings momentum. The company delivered Q2 2026 EPS of $6.48, beating estimates by 6.6%, while revenue growth accelerated to $14.93B in 2025. Analyst consensus remains overwhelmingly bullish with 90% buy ratings and a $236.63 price target, representing 18% upside potential. Recent news highlights operational excellence and production growth guidance increases.

The outlook remains positive with production growth and debt reduction supporting valuation expansion. Key risks include oil price volatility and execution challenges amid global supply disruptions. Institutional interest remains strong with recent positions from Balefire LLC, though some trimming occurred from Bank of Nova Scotia. The combination of earnings beats, improved guidance, and favorable technicals suggests continued upward momentum.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX